Secondary analysis of HELIOS-B (654 patients with ATTR cardiomyopathy, vutrisiran vs placebo): no significant evidence that tafamidis, SGLT2 inhibitors, MRAs, beta-blockers or RAS inhibitors modified vutrisiran's effect on death and recurrent CV events (all P-interaction ≥0.59).
Secondary analysisn = 654
Abovich et al. Influence of Disease-Modifying Therapy on the Efficacy of Vutrisiran in Transthyretin Cardiac Amyloidosis